CG Oncology Statistics
Total Valuation
CG Oncology has a market cap or net worth of $4.13 billion. The enterprise value is $3.52 billion.
Important Dates
The last earnings date was Friday, November 14, 2025, before market open.
| Earnings Date | Nov 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CG Oncology has 80.67 million shares outstanding. The number of shares has increased by 60.24% in one year.
| Current Share Class | 80.67M |
| Shares Outstanding | 80.67M |
| Shares Change (YoY) | +60.24% |
| Shares Change (QoQ) | +0.66% |
| Owned by Insiders (%) | 0.81% |
| Owned by Institutions (%) | 95.59% |
| Float | 65.44M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1,928.72 |
| Forward PS | n/a |
| PB Ratio | 5.92 |
| P/TBV Ratio | 6.23 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1,619.14 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 22.79, with a Debt / Equity ratio of 0.01.
| Current Ratio | 22.79 |
| Quick Ratio | 22.30 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -24.74% and return on invested capital (ROIC) is -18.28%.
| Return on Equity (ROE) | -24.74% |
| Return on Assets (ROA) | -17.56% |
| Return on Invested Capital (ROIC) | -18.28% |
| Return on Capital Employed (ROCE) | -25.75% |
| Weighted Average Cost of Capital (WACC) | 11.58% |
| Revenue Per Employee | $19,239 |
| Profits Per Employee | -$1.34M |
| Employee Count | 113 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +77.08% in the last 52 weeks. The beta is 1.34, so CG Oncology's price volatility has been higher than the market average.
| Beta (5Y) | 1.34 |
| 52-Week Price Change | +77.08% |
| 50-Day Moving Average | 45.95 |
| 200-Day Moving Average | 34.67 |
| Relative Strength Index (RSI) | 54.15 |
| Average Volume (20 Days) | 1,471,091 |
Short Selling Information
The latest short interest is 9.39 million, so 11.64% of the outstanding shares have been sold short.
| Short Interest | 9.39M |
| Short Previous Month | 12.92M |
| Short % of Shares Out | 11.64% |
| Short % of Float | 14.35% |
| Short Ratio (days to cover) | 7.38 |
Income Statement
In the last 12 months, CG Oncology had revenue of $2.17 million and -$151.48 million in losses. Loss per share was -$2.03.
| Revenue | 2.17M |
| Gross Profit | -112.89M |
| Operating Income | -180.12M |
| Pretax Income | -151.48M |
| Net Income | -151.48M |
| EBITDA | -179.53M |
| EBIT | -180.12M |
| Loss Per Share | -$2.03 |
Full Income StatementBalance Sheet
The company has $680.26 million in cash and $7.24 million in debt, with a net cash position of $673.02 million or $8.34 per share.
| Cash & Cash Equivalents | 680.26M |
| Total Debt | 7.24M |
| Net Cash | 673.02M |
| Net Cash Per Share | $8.34 |
| Equity (Book Value) | 687.64M |
| Book Value Per Share | 8.78 |
| Working Capital | 665.26M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$116.79 million and capital expenditures -$336,000, giving a free cash flow of -$117.13 million.
| Operating Cash Flow | -116.79M |
| Capital Expenditures | -336,000 |
| Free Cash Flow | -117.13M |
| FCF Per Share | -$1.45 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -8,285.33% |
| Pretax Margin | -6,967.99% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CG Oncology does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -60.24% |
| Shareholder Yield | -60.24% |
| Earnings Yield | -3.61% |
| FCF Yield | -2.79% |
Analyst Forecast
The average price target for CG Oncology is $70.00, which is 36.64% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $70.00 |
| Price Target Difference | 36.64% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (5Y) | 224.06% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
CG Oncology has an Altman Z-Score of 29.99 and a Piotroski F-Score of 3.
| Altman Z-Score | 29.99 |
| Piotroski F-Score | 3 |
